Physician profile
Hamza Sheikh
NPI 1548471089
$7,114.00
in general payments reported to CMS, 2019-2025
49 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $110 · 2021: $111 · 2022: $2,096 · 2023: $1,637 · 2024: $1,699 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,602.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $819.17 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $751.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $707.28 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $539.85 | 2022-2025 | Tremfya |
| Ucb, INC. | $456.65 | 2022-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.55 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $299.02 | 2019-2025 | |
| Insulet Corporation | $293.92 | 2019-2025 | Omnipod |
| Dexcom, INC. | $258.57 | 2022-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $195.33 | 2022-2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $189.72 | 2022-2025 | Saphnelo, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $185.68 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $177.34 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.37 | 2023-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $141.74 | 2019-2021 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $127.47 | 2022-2024 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $116.36 | 2022-2024 | Strensiq |
| Radius Health, INC. | $103.80 | 2022-2023 | Tymlos |
| Aurinia Pharma U.S., INC. | $103.18 | 2022-2024 | Lupkynis |
| Medtronic, INC. | $84.62 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $69.99 | 2022-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $69.83 | 2019 | |
| Ascendis Pharma Endocrinology INC | $65.98 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $64.42 | 2022-2023 | Tepezza |
| Mannkind Corporation | $63.49 | 2020-2025 | |
| Medtronic Minimed, INC. | $56.63 | 2019-2020 | |
| Madrigal Pharmaceuticals | $52.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Astellas Pharma US INC | $50.59 | 2025 | Veozah |
| Fresenius Kabi USA, LLC | $47.88 | 2025 | |
| Beta Bionics, INC. | $45.81 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ani Pharmaceuticals, INC. | $44.24 | 2025 | Purified Cortrophin Gel |
| Recordati_rare_diseases_inc. | $42.98 | 2022-2023 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $40.38 | 2025 | |
| Amneal Pharmaceuticals LLC | $40.06 | 2024 | Unithroid |
| Tandem Diabetes Care, INC. | $37.30 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $27.50 | 2024 | |
| Genentech USA, INC. | $24.15 | 2024 | Actemra |
| Sequel Med Tech, LLC | $23.14 | 2025 | Twiist |
| Amryt Pharma Holdings Ltd | $20.56 | 2022 | |
| Fidia Pharma USA INC. | $20.18 | 2025 | Hymovis, Triluron |
| Nevro Corp. | $17.75 | 2022 | |
| Antares Pharma, INC. | $16.15 | 2019 | |
| Currax Pharmaceuticals LLC | $15.83 | 2025 | Contrave |
| Cequr Corporation | $15.61 | 2024 | Cequr Simplicity |
| Abbvie INC. | $15.39 | 2022 | |
| Organon LLC | $14.57 | 2024 | |
| Mallinckrodt Hospital Products INC. | $14.12 | 2022 | |
| Eusa Pharma (US) LLC | $13.72 | 2022 | |
| Acella Pharmaceuticals, LLC | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.